文献速递基础与转化研究临床试验与 GCP

基因校正造血干细胞在未预处理范可尼贫血患者中成功植入

Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia.
PubMed 文献 · Nat Med · 2019-09-09

本研究为临床试验(NCT03157804),在未接受预处理的范可尼贫血A亚型患者中,采用慢病毒介导的造血基因治疗,证明基因校正的造血干细胞具有植入和增殖优势,纠正了血液和骨髓细胞的表型,并在基因标记水平最高的患者中观察到骨髓衰竭进展停滞。

要点

  • 慢病毒介导的基因治疗在未预处理范可尼贫血A亚型患者中可重复地赋予基因校正造血干细胞植入和增殖优势。
  • 插入位点分析显示校正造血干细胞的多能性,且再增殖优势并非源于治疗原病毒的基因毒性整合。
  • 在基因标记水平最高的患者中观察到骨髓衰竭进展停滞。

核心结论

  • 基因校正造血干细胞在未预处理范可尼贫血患者中的渐进性植入支持基因治疗应成为这一危及生命疾病的创新低毒性治疗选择。

研究设计与样本

  • 临床试验(ClinicalTrials.gov NCT03157804;欧洲临床试验数据库 2011-006100-12),在未接受预处理的范可尼贫血A亚型患者中开展慢病毒介导的造血基因治疗。

主要发现

  • 慢病毒介导的造血基因治疗可重复地赋予基因校正造血干细胞植入和增殖优势。
  • 插入位点分析揭示校正造血干细胞的多能性,并显示其再增殖优势并非由于治疗原病毒的基因毒性整合。
  • 血液和骨髓细胞的表型纠正表现为造血祖细胞和T淋巴细胞获得对DNA交联剂的抗性。
  • 在基因标记水平最高的患者中观察到骨髓衰竭进展停滞。

临床怎么用

  • 原文结论认为基因治疗应成为该危及生命疾病的创新低毒性治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fanconi anemia (FA) is a DNA repair syndrome generated by mutations in any of the 22 FA genes discovered to date1,2. Mutations in FANCA account for more than 60% of FA cases worldwide3,4. Clinically, FA is associated with congenital abnormalities and cancer predisposition. However, bone marrow failure is the primary pathological feature of FA that becomes evident in 70-80% of patients with FA during the first decade of life5,6. In this clinical study (ClinicalTrials.gov, NCT03157804 ; European Clinical Trials Database, 2011-006100-12), we demonstrate that lentiviral-mediated hematopoietic gene therapy reproducibly confers engraftment and proliferation advantages of gene-corrected hematopoietic stem cells (HSCs) in non-conditioned patients with FA subtype A. Insertion-site analyses revealed the multipotent nature of corrected HSCs and showed that the repopulation advantage of these cells was not due to genotoxic integrations of the therapeutic provirus. Phenotypic correction of blood and bone marrow cells was shown by the acquired resistance of hematopoietic progenitors and T lymphocytes to DNA cross-linking agents. Additionally, an arrest of bone marrow failure progression was observed in patients with the highest levels of gene marking. The progressive engraftment of corrected HSCs in non-conditioned patients with FA supports that gene therapy should constitute an innovative low-toxicity therapeutic option for this life-threatening disorder.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Río P, Navarro S, Wang W, et al. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. Nat Med. 2019. PMID: 31501599. doi:10.1038/s41591-019-0550-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。